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For centuries, Malaria has continued to be one of the most deadly infectious diseases in 
the world.   Almost all of the current antimalarial drugs target the asexual blood stages of the 
Plasmodium parasite responsible for the clinical pathology of malaria, but nearly all have no 
activity against the mature gametocyte or sexual stage that is responsible for the transmission of 
the parasite through the mosquito vector.  Renewed interest in global eradication of malaria has 
turned some of the focus on blocking transmission.  We have developed transgenic Plasmodium 
berghei that expresses luciferase under the control of gametocyte-specific promoters.  Pb920Lux 
is a transgenic parasite that expresses luciferase in both male and female gametocytes, while 
Pb610Lux is a transgenic parasite that expresses luciferase in the male gametocyte.  
Immunofluorescence assay (IFA) shows luciferase is expressed in some parasites and in 
accordance with a previous study, suggest these may be gametocytes.  These transgenic parasites 
were then used in a luciferase-based drug assay.  Seven known antimalarial drugs were used to 
confirm the validity of the assay.  Four of the known drugs had gametocidal activity, while three 
of the drugs have no gametocidal activity.  We first created a dose response using the Pb920Lux 
and Pb610Lux along with PbGFPLuxcon as our control. From there we calculate the IC50 values 
of these drugs and compared them to the IC50 values calculated using PbGFPLuxcon (control).  
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As expected, the transgenic parasites showed significant gametocidal activity in the four known 
drugs and no significant activity in the three non-gametocidal drugs.  We confirmed this finding 
by calculating the percentage of parasites and gametocyte by light microscope and compared 
these to our findings with the luciferase-based assay.  Next we analyzed four unknown drugs and 
found that they contain no gametocidal activity.  The public health importance of developing a 
luciferase-based assay specific for gametocytes is to provide ??simple and efficient method of 
detecting gametocidal drugs in order to prevent the transmission of malaria. 
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1.0  INTRODUCTION 
1.1 DESCRIPTION OF THE PROBLEM 
Despite major progress to control and prevent malaria through insecticide-impregnated bed nets 
and combinational drug therapies, an estimated 3.3 billion people remain at risk for contracting 
malaria [1].  Malaria accounts for an estimated 0.5-2.5 million deaths each year the majority of 
cases are children in sub-Saharan Africa [2].  Most malaria endemic countries are located along 
the equator in tropical regions (Fig. 1).  The emergence and the spread of resistance to affordable 
antimalarial drugs have contributed to the sharp increase in malaria-caused mortality [2].  In 
recent years there has been a renewed interest in finding new and improved ways to eradicate 
malaria with an increased interest on interrupting the transmission from human host to mosquito 
vector.  This is due in part to a significant increase in the prevalence of gametocytes after the 
widespread partial use of some antimalarial therapies, long duration of infection, anemia and 
partially effective immune responses [3].  There is evidence that antimalarial drug resistance 
spreads because of the greater transmission potential of resistant parasites in the presence of the 
drug [4].  Although, scientific rationale for targeting the sexual stage of Plasmodium is becoming 
clear, most of the current drugs available targets the asexual blood stage and are eliminated 
slowly from the body.  Therefore, if they are used intensely in malaria endemic areas, a 
significant proportion of the population will have variable amounts of antimalarial drugs in their 
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systems making these concentrations act as a selective filter for favoring transmission of drug 
resistant gametocytes.  
1.2 MALARIA 
Malaria is a mosquito-borne infectious disease of both humans and animals.  The disease is a 
result of the parasite multiplying within the red blood cells.  Symptoms of malaria include chills, 
fever, headache, malaise, fatigue, and muscular pain.  In humans, symptoms can range from mild 
to severe which includes coma or death.  The symptoms can fist appear 10-16 days after an 
infectious mosquito bite [5]. There are five known species that can infect and be transmitted to 
humans.  The most severe is Plasmodium falciparum, while other malarial diseases caused by 
Plasmodium vivax, Plasmodium ovale and Plasmodium malariae are generally milder. Unlike P. 
falciparum, P. vivax and P. ovale can develop into dormant liver stages that can be reactivated 
after two years (P. vivax) and four years (P. ovale) of being symptomless [6].  The fifth species 
called Plasmodium knowlesi is a zoonotic disease caused by malaria in macaques.  P. knowlesi 
can resemble either P. falciparum or P. malariae under light microscope and therefore 
polymerase chain reaction (PCR) is required for confirmation [6].   
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Figure 1. Spatial Distribution of P. falciparum Endemicity. 
Map of malaria endemic countries with the heaviest rate of infection located mostly in sub-
Saharan Africa [7]. 
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1.2.1 Plasmodium Lifecycle 
Plasmodium spp. has a very complex lifecycle, one in the host and the other in the mosquito 
vector (Fig. 2).  The lifecycle of malaria begins when the mosquito takes a blood meal from the 
vertebrate host that contains mature gametocytes.  The gametocytes then migrate to the 
mosquito’s midgut and become male and female gametes.  The gametes then undergo 
fertilization to create zygotes and ookinetes.  The ookinetes migrate to the exterior of the midgut 
and develop into oocyst and oocysts that contain sporozoites.  Once the mosquito takes a blood 
meal, the sporozoites leave the salivary glands and enter into the blood stream to invade liver 
cells.  Within the liver cells, the parasite undergoes development into trophozoites and then 
schizonts.  This is the liver stage of the parasite.  Once the schizonts mature they are released 
back into the blood stream as merozoites to become blood stage parasites in order to infect red 
blood cells (RBC).  Once they infect RBCs, they go through the process of forming rings, 
trophozoites, and schizonts.  This stage of the lifecycle is also known as the asexual blood stage.  
Once they develop into schizonts, the parasites can either become merozoites that are released to 
reinfect more RBCs or enter into the gametocyte stage.  This part of the blood stage is known as 
the sexual blood stage.  The gametocytes circulate in the blood in a state of developmental arrest 
until another mosquito takes a blood meal from the infected person and the cycle begins again.   
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Figure 2. Plasmodium spp. lifecycle in human host. 
All Plasmodium spp. have very similar life cycle, where they both require two stages in order to complete 
their life cycle.  Plasmodium spp. has three main cycles: (A) Exo-erythrocytic and (B) erythrocytic, (C) 
Sporogonic [8].   
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1.2.2 Comparison of Rodent and Human Plasmodia 
Rodent and human Plasmodium has been shown to be analogous in most essential aspects of 
structure, physiology and lifecycle [9].  The basic biology of P. berghei (rodent) and P. 
falciparum (human) is very similar.  Rodent parasites have well characterized clones and 
genetically modified mutant lines, including transgenic parasites expressing reporter genes like 
luciferase.  The manipulation of the whole lifecycle of the rodent parasite is simpler and safer 
than the human parasite.  In addition, their molecular basis of drug-sensitivity and resistance is 
similar [10].  There are some major advantages to working with rodent parasites.  For one, the 
gametocyte development takes less time from 48 hours - 12 days with P. falciparum to 26 - 30 
hours with P. berghei [10].  In addition to the difference in gametocyte developmental time, the 
two morphologies are distinct.  P. falciparum gametocytes take on a banana shape, while in P. 
berghei gametocytes are oval shaped (Fig. 3). 
1.2.3 Gametocytogenesis of P. berghei and P. falciparum 
During each asexual cycle of P. berghei, a small portion of the parasites halt asexual 
multiplication and start to differentiate into sexual cells.  The haploid macrogametocytes 
(female) and the microgametocytes (male) are the precursor cells of the female and male 
gametes.  There seems to be evidence that approximately 5-25% of the P. berghei parasites 
commit to sexual differentiation [11].  This somewhat fixed percentage of sexual development is 
different from P. falciparum, where there are periods of purely asexual multiplication that are 
alternated with periods of gametocyte production [10]. In comparison P. berghei has a much 
shorter period for gametocytes development.  During the first 16 hours of development it is 
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difficult to distinguish gametocytes from asexual trophozoites using a light-microscope or 
electron-microscope [12].  After 18-22 hours sex-specific gametocytes fill the erythrocyte [13].  
Only after 24 hours do the differentiating features of the female and male gametocytes become 
apparent [13].  There has been some evidence that P. berghei commit to sexual development in 
the trophozoite stage, while P. falciparum commitment is during the previous trophozoite cycle 
[9].  In P. berghei, there is no known molecular mechanism that induces and regulates the switch 
from asexual to sexual, although there seems to be evidence that in both P. berghei and P. 
falciparum, environmental factors have an influence [12]  Gametocytogenesis has been 
observed, depending on clinical symptoms [14].  Several studies have identified different 
potential mechanisms, such as immune stress response, acting on gametocytogenesis through the 
effects of lymphocytes [15], and hematological disruptions like anemia and lysis of RBC [16-
18], all within the dynamics of a Plasmodium infection. 
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Figure 3. P. berghei morphology at different blood stages? 
Stages shown are from synchronized blood stage infections of the ANKA strain of P. berghei at different 
hours post infection (hpi) [13]. 
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1.3 ANTIMALARIAL DRUGS 
Antimalarial therapies play a critical role in the control, prevention and ultimately elimination of 
malaria.  The major problem is that if the current class of drugs loses their effectiveness then 
control, prevention and elimination may no longer be possible.  Most drugs that are used as 
antimalarial therapies affect the blood stage or asexual stages of Plasmodium, while only a few 
are effective against gametocytes.  Although, if treated early they can be effective against the 
transmission of malaria, but this is not straightforward.  For P. falciparum, all anti-malarial drugs 
which kill the asexual stages also kill the early stages of the gametocytes, but are not as effective 
in the mature gametocytes [4].  Even a 95% reduction in transmission from 500 to 25 infective 
bites per year won’t yield noticeable change in the incidence or prevalence rates; this is also in 
part due to asymptomatic gametocyte carriers [4].  Asymptomatic gametocyte carriers are people 
who are infected with gametocytes, but they don’t show any malarial symptoms.  In addition, a 
partially effective antimalarial drug not only has decreased activity against the asexual blood 
stage, it also adds a sufficient amount of stress for the parasite to form drug resistant 
gametocytes.  At least one male gametocyte’s progeny (eight microgametes) and one female 
gametocyte are required in a mosquito blood meal for an infection to occur (approx. 2-3 µL) [4]. 
Therefore, the gametocyte density of one per µL is well below what can be detected by routine 
microscopy [19].  Thus the combination of reducing the asexual stage as well as the sexual stage 
is the best way to reduce transmissibility, but this is not straightforward, due to variations in 
immunity, pharmacokinetics and pharmacodynamics causing’ noticeable capriciousness in 
transmissibility as it relates to the activity of antimalarial drugs [14].  Three components need to 
be considered when looking at the effects of antimalarial drugs on transmissibility; a) an activity 
against asexual stages and early gametocytes, b) activity against mature gametocytes and c) 
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sporontocidal effects in the mosquito [4].  Table 1 shows a summary of the drugs used in this 
study that reflects most of the commonly used drugs to treat malaria. 
1.3.1 Pyrimethamine 
A 4-aminoquinoline folic acid antagonist used to treat acute malaria [20].  It is most commonly 
used to treat uncomplicated, chloroquine resistant, P. falciparum.  Pyrimethamine is most 
effective against erythrocytic schizonts and contains no gametocidal activity [20].  It inhibits the 
dihydrofolate reductase of plasmodia by blocking the biosynthesis of purines and pyrimidines 
needed for DNA synthesis and cellular multiplication resulting in the failure of nuclear division 
[20].  Pyrimethamine has been widely used as a monotherapy in mass drug administrations in 
Asia and South America, which may have been a contributing factor in the spread of 
pyrimethamine resistance.  Mutation in the binding affinity of pyrimethamine to dihydrofolate 
reductase contributes to the widespread resistance.  Pyrimethamine is most active by hepatic 
metabolism and has a half-life of 96 hours.  It is considered a slow-acting drug.   
1.3.2 Primaquine 
This drug is an 8-aminoquinoline that is orally given as a radical cure and preventive for the 
relapse of P. vivax and P. ovale [21].  It is one of the oldest of the currently used antimalarial 
drugs, but also the least well understood.  It was first developed to prevent P. vivax relapse in 
U.S. soldiers returning to the United States from World War II and the Korean War [22].  It has 
also been used to prevent the transmission of P. falciparum.  Its adverse effects include anemia 
and gastric intestinal (GI) disturbances [20].  Primaquine is used in combination with 
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chloroquine for the treatment of all types of malaria.  It works by interfering with the parasite’s 
mitochondria, the part responsible for supplying energy [20].  Primaquine not only kills the 
hepatic form of P. vivax and P. ovale, it also kills the gametocytes of all types of plasmodia.  It is 
least effective against the asexual blood stage and therefore is always used in conjunction with a 
schizonticide [23].  Although, its mechanism of action is still not well understood, it is thought to 
bind or alter the properties of protozoal DNA [23].  Its active metabolites (several have been 
reported) have been shown to be more potent than primaquine [21].  It has a half-life of 3.7 - 7.4 
hours.  Primaquine is the only known drug with fast and direct activity against P. falciparum 
gametocytes and high gametocyte activity in all other species [23]. 
1.3.3 Quinine 
It is an alkaloid and active ingredient in extracts derived from the bark of the chinchona tree.  It 
has been in use since 1633 as an antimalarial drug [24].  It is primarily used to treat life-
threatening chloroquine-resistant P. falciparum malaria.  It acts as a blood schizonticide in P. 
vivax and P. ovale and a poor gametocytocidal prophylaxis [24].  Due to being a weak base, 
quinine is concentrated in the food vacuoles of Plasmodium [24].  As a schizonticidal therapy, it 
is less effective and more toxic than chloroquine, making it more effective in the management of 
severe P. falciparum malaria in areas with known chloroquine resistance [24].  The suspected 
mechanism of action for quinine and other related antimalarial drugs is that they interfere with 
the parasite’s ability to break down and digest hemoglobin [24],  ultimately starving as well as 
building up toxic levels of partially digested hemoglobin within the parasite [24].  Over 80% of 
quinine is metabolized by the liver into 3-hydroxyquinine.  It has a half-life of 18 hours and it is 
known to cause drug induced thrombocytopenia (DIT).  Quinine induces the production of 
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antibodies against glycoprotein (GP) Ib-IX complex or more rarely the platelet-glycoprotein 
complex (GP) IIb-IIIa, resulting in the increase in platelet clearance leading to thrombocytopenia 
[25]. 
1.3.4 Atovaquone 
Atovaquone is a relatively new antimalarial drug that is able to block the cytochrome in the 
parasite.  It acts by affecting mitochondrial electron transport and parallels processes like ATP 
and pyrimidine biosynthesis [26].  Unfortunately, a single nucleotide mutation in the parasite’s 
cytochrome b gene causes drug-resistance [27].  Atovaquone is only used in combination with 
proguanil (an antimalarial drug that is effective against the asexual blood stage) resulting in a 
very high cure rate in uncomplicated P. falciparum [26].  There has been some evidence of 
limited metabolism, but no metabolites have been identified [26].  Atovaquone has antimalarial 
activity against the asexual and sexual blood stages of Plasmodium.  In addition, this drug 
prevents the formation of sporozoites by interfering with oocyst development in the mosquito 
[4].  The unaffordability of this drug to third world countries that need it the most may be  one of 
the reasons for the delay in drug-resistance [27, 28].  Atovaquone has a half-life of 2.2 – 3.2 days 
due to a presumed entrohepatic cyclin and eventual fecal elimination [26].    
1.3.5 Tetracycline 
This is a broad spectrum polyketide antibiotic produced by Streptomyces genus of 
Actinobacteria.  It is a cyclin antibiotic that targets the apicoplast ribosome, resulting in 
abnormal cell division [22].  It is normally used as a prophylaxis because of delayed antimalarial 
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effects on the apicoplast gene.  If used as a treatment it must be combined with other antimalarial 
drugs like quinine.  Tetracycline has been reported to cause hemolytic anemia, a condition in 
which red blood cells are prematurely destroyed [29, 30].  Tetracycline is a slow-acting drug that 
has antimalarial activity against the asexual stage of Plasmodium. 
1.3.6 Artesunate 
Artesunate is a part of the artemisinin group of antimalarial treatments.  Artemisinin, also known 
as Qinghaosu in Chinese, is found in the leaves of Artemisia annua.  It was one of nearly 5,000 
traditional Chinese medicines used to treat malaria and the only one found to be effective.  
Artesunate is a semi-synthetic derivative of artemisinin.  It is used to treat severe malaria in areas 
where transmission is low.  Artesunate is a sesquiterpene lactone containing an unusual peroxide 
bridge, which is believed to be the mechanism of action [29].  Dihydroartemisinin is the active 
metabolite of all artemisinin compounds.  This category of drugs is known for their fast action in 
clearing the blood of asexual and sexual parasites.  Both of these characteristics allow for the 
minimization of drug-resistance, but combinational treatment is still highly recommended. 
1.3.7 Amodiaquine 
Amodiaquine is used for acute malarial attacks in non-immune subjects [31].  It is a 4-
amioquinoline that is similar to chloroquine in structure and activity.  It has been in use for over 
40 years [31].  Amodiaquine has been shown to be just as effective as chloroquine, as well as 
effective against some chloroquine-resistant strains.  The mechanism of action for amodiaquine 
has yet to be determined.  The 4-aminoquinolines can depress cardiac muscle, impair cardiac 
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conductivity and produce vasodilation resulting in hypotension [32].  Amodiaquine is thought to 
inhibit heme polymerase activity causing the accumulation of free heme, which is toxic to the 
parasite [31].  It has been found to be effective against immature gametocytes, but ineffective 
against mature gametocytes of P. falciparum [25].  Hepatic biotransformation of amodiaquine to 
desethylamodiaquine (principal biologically active metabolite) is the main route of clearance 
with little escaping untransformed.  It has a half-life of 5.2  ± 1.7 minutes and therefore a fast 
acting drug [31]. 
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Table 1. Summary of Antimalarial Drugs Used in this Study 
 
 
 
1.3.8 Need for Gametocidal drugs 
The need to develop and discover new antimalarial therapies can be overwhelming.  The cost of 
a new drug discovery exceeds $750 million per new chemical compound which adds to the 
burden that third world countries already face [33].  In addition, the success rate for new 
chemotherapies to move into clinical trials is extremely low.  This is true for all new drugs, but it 
Pyrimethamine*
Radical cure and 
casual 
prophylaxis
Y Y
Primaquine
Radical cure and 
casual 
prophylaxis
Y N
Quinine
Radical cure 
N Y
Atovaquone
Radical cure and 
casual 
prophylaxis
Y N
Tetracycline
Radical cure 
N N
Artesusnate
Radical cure 
N Y
Amodiaquine
Radical cure and 
suppressive 
prophylaxis
Y Y
Liver MetabolizeDrug Resistance
 Blood Stage Specificity
Asexual Gametocytes Use
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is significantly worse for antimalarial therapies with Malarone (GlaxoSmithKline, UK) the 
newest drug to be approved by the FDA in the last decade [33].  Malarone is a combinational 
therapy consisting of atovaquone and proguanil hydrochloride [26].  Furthermore, most of the 
commercially available antimalarial drugs target the asexual stage with very few drugs having 
gametocidal activity.  Currently, primaquine is the only drug that has a direct activity against 
gametocytes.  In order to prevent the transmission of malaria to new hosts, additional 
antimalarial drugs with gametocidal activity need to be discovered.  In order to improve the 
search for new antimalarial therapies, simple and efficient assays need to be developed. 
1.4 DRUG SCREENING ASSAYS 
For decades the effectiveness of antimalarial therapies has been measure in vitro by quantifying 
the parasites uptake of a radioactive substrate as a measure of viability in the presence of the test 
drug [34].  [3H] Hypoxanthine was the most widely used radiolabel, but in more recent years the 
switch has been toward fluorescence or luminescence-based assays.  While the previous method 
was both reliable and accurate, the more recent methods have proven to not only be effective, but 
also simple, efficient and inexpensive.  Recent advances in chemical synthesis and identification 
of potential drug compounds has increased the demand for high-throughput screening (HTS) 
assays.  The trend for HTS assays thus far are based on fluorescence or luminescence detection 
methods.  Although both methods are effective, fluorescent assays can have a higher background 
because of the strong light emissions, in contrast, luminescent assays are virtually absent of any 
background noise [2].  In addition, luminescent assays have greater sensitivity in signal 
detection, making miniaturization of the assay possible [2].  Another way to measure the effects 
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of antimalarial drugs on asexual and sexual Plasmodium is fluorescence activated cell sorting 
(FACS).  FACS is a technique for counting and analyzing cell populations.  Although this 
technique is highly accurate, it can be costly and time consuming.  Therefore, developing a 
luciferase-based assay to screen for antimalarial drugs with gametocidal activity would allow for 
quick and easy analysis of the drug’s effectiveness. 
 
1.4.1 Luciferase-based Antimalarial Assay 
Firefly luciferase is the most widely used bioluminescent reporter.  This enzyme catalyzes a two-
step oxidation reaction to produce light in the green to yellow region or 550 – 570 nm [35].  
According to Promega’s Bioluminescence Reporter manual, the first step involves the activation 
of the luciferyl carboxylate by ATP, which yields a reactive mix anhydride.  The second step is 
the activation of the intermediate with oxygen to create a transient dioetane.  The dioxetene 
breaks down to the oxidized products, oxyluciferin and CO2 [35].  Several studies have used 
luciferase as a reporter to analyze different drug effects on mixed blood stages of Plasmodium 
using both P. berghei and P. falciparum respectively [36, 37].  There have been no reported 
studies that were able to analyze the effects of drug compounds throughout the early and late 
stages of gametocyte development.  
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2.0  STATEMENT OF THE PROJECT 
Antimalarial drug screenings can be time-consuming and complicated.  Screenings usually 
involve the use of whole cell assays to determine the sensitivity of drugs on in vitro growth using 
P. falciparum and/or testing the in vivo sensitivity of selected drugs in small animal models 
using P. berghei [37].  Previous studies mostly focused on the mixed blood stage (gametocytes 
plus asexual) of Plasmodium or just on the asexual stages.  We have not found any drug studies 
that focus on P. berghei gametocytes.  Our goal is to find a simple and effective way to screen 
for potentially new drugs that decrease the presence of gametocytes as well as possibly 
preventing gametocytemia.  Gametocytemia is a sensitive indicator of emerging drug resistance 
due to measurable increase in transmission, and more specifically resistance transmission is seen 
before there are detectable changes in treatment failure rates [4].  In this study, we created a 
transgenic P. berghei that contains a gametocyte specific promoter attached to a luciferase 
reporter.  We tested the expression of this reporter in comparison with PbGFPLuxcon, a wild-
type strain of P. berghei that expresses luciferase constitutively throughout its lifecycle, to 
known drugs with and without gametocidal activity. We hypothesized that antimalarial drugs 
that have gametocidal activity will have similar IC50 values in the transgenic parasites as they do 
in wild-type, while the IC50 value of antimalarial drugs with non-gametocidal activity will be 
higher in the transgenic parasite as compared to the wild-type.  Lastly, we believe that novel 
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antimalarial drugs can be identified using these transgenic parasites in a larger scale luciferase-
based screening.  To test these hypotheses, our objectives were: 
Specific Aim 1: Construct gametocyte specific luciferase expressing transgenic parasite 
Specific Aim 2: Develop and test the sensitivity of a standardized luciferase-based drug 
assay using the transgenic parasites from AIM 1. 
Although there has been great advancement in the study of asexual parasites in P. falciparum, 
the sexual stage has not had such advancement.  The slow progression in the study of P. 
falciparum gametocytes is predominately due to the difficulties of differentiating the early stage 
gametocytes from the asexual as well as obtaining an adequate number of gametocytes [38].  
There are a few advanced techniques for developing P. falciparum gametocytes, but 
unfortunately they are difficult to set up, require costly equipment and have a high rate of 
contamination with bacteria and fungus [39].  Whereas, P. berghei has shown a fixed range of 
gametocytes production, it can be grown in vitro as well as in vivo and it reacts similarly to 
antimalarial drugs.  We believe that this simple and efficient luciferase-based screening will 
contribute to the finding of new drug compounds that can interfere with the transmission of 
Plasmodium. 
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3.0  MATERIALS AND METHODS 
3.1 CONSTRUCTION OF TRANSGENIC PARASITES 
3.1.1 Identify conserved Plasmodia gene promoters 
A literature review was performed to find promoters that were exclusively expressed in both 
gametocyte sexes, as well as expressed in only male and only female gametocytes.  It was shown 
through proteome analysis and confirmed with GFP expression that promoters 
PBANKA_061920 (PB000198.00.0), PBANKA_130070 (PB000652.01.0) and 
PBANKA_041610 (PB000791.03.0) are exclusively expressed in both gametocytes, female 
gametocytes and  male gametocytes respectively [40].  PBANKA_061920 is a conserved 
hypothetical protein gene, PBANKA_130070 is a LCCL domain-containing protein gene, and 
PBANKA_041610 is a putative chain dynein-phosphatase gene.  All three genes are syntenic and 
have orthologs that are found in P. falciparum  
3.1.2 Transgenic Parasites 
Two different transgenic parasite lines of P. berghei are being used in this study, Pb920Lux and 
Pb610Lux.  Both lines express firefly luciferase (Luc-IAV) and have been generated in reference 
clone of the ANKA strain.  The constructs express luciferase under the control of a conserved 
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hypothetical protein promoter (Pb920Lux) and the putative heavy chain dynein-phosphatase 
promoter (Pb610Lux).  A plasmid construct pL0027 was used, which contain a pyrimethamine-
resistant form of the dihydrofolate reductase (dhfr-ts) gene of Toxoplasma gondii as a drug-
selectable marker.  The eef1αa promoter found in pL0027, which is a constitutive promoter that 
is active throughout all the blood stages, was exchanged for the promoters PBANKA_06920 and 
PBANKA_071610.  The insert containing the PBANKA_130070 promoter was unstable and 
therefore was unable to produce a plasmid construct.  
The promoters were amplified by PCR using primers for PBANKA_061920 (5’ forward: 
CCACATGTCCCGGGGATATCAATTTTTATAGTTGTTGCAC and 5’ Reverse: 
CGCGGATCCTTTTATATCTGTCTTATTAAGATTC) that produces a 1,067 base pairs (bp) 
fragment and PBANKA_071610 (5’ forward: 
CCACATGTGATATCTAGTGGAAGTAAAACCGAGC and 5’ Reverse: 
CGCGGATCCTTTTTATCATTTGGATAATTAATTC) that produces a 1,992 bp fragment.  
The promoter fragments were ligated at the BamHI and EcoRV/SmaI site.  The constructs were 
briefly transformed into Hβ10 competent cells (NEB) and identified using the ampicillin 
resistance gene found on the pL0027.  The appropriate plasmids were linearized using the unique 
ApaI restriction site and transfected into PBANKA schizonts using electroporation using Amaxa 
nucleofactor [41].   
The parasites were cultured using Swiss mice under a four-day treatment of 
pyrimethamine drinking water until parasitemia reached approximately 5%.  Afterward, a 
luciferase assay was performed to check luciferase expression.  In addition, the transgenic 
parasites were sequenced to confirm the insertion of the promoter.  Two transgenic lines of 
Pb610Lux and one of Pb920Lux were further characterized.  PbGFPLuxcon (MRA-868) is a 
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transgenic parasite that constitutively expresses a GFP-luciferase fusion protein under the control 
of an ef-1αa promoter [42].  This transgenic parasite doesn’t contain a pyrimethamine resistance 
(pyrR) gene and was obtained from MR4 (www.MR4.org), a depository for transgenic malaria 
parasites.   
 
3.1.3 Characterization 
The vector was introduced into the blood stage genome by targeted integration of the fragment 
into the d-ssu-rrna of P. berghei, which is present in the vector.  The c-ssu-rrna and d-ssu-rrna are 
95% identical [43] and therefore this vector can integrate either into the c- or d-rrna gene unit 
(Fig. 2).  Three predicted integration events in the transgenic parasite line were confirmed by 
PCR analysis using integration primers: L665, L740, L635, and L739 [43].  L635 (5’-
TTTCCCAGTCACGACGTTG) and L739 (5’-TTTGGATATTTTCATATATG) verifies 5’ 
insertion of the vector and L665 (5’-GTTGAAAAATTAAAAAAAAAC) and L740 (5’-
CTAAGGTACGCATATCATGG) verifies 3’ insertion of the construct.  To measure the amount 
of wild-type, any parasite without the insertion of the construct, primers L739 and L740 of wt c- 
and d-ssu-rrna were used. 
 
3.1.4 IFA 
To confirm that luciferase is being expressed in gametocytes an IFA was performed.  After the 
blood is harvested from the mice, 25 µL in 75uL of media was used and washed twice with 
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500uL of PBS.  The cells are fixed with 0.1% triton X-100 in PBS, then washed twice and 
blocked with 5% rabbit serum in PBS.  RBCs were incubated in PbHSP70 mAb 1:40 and 
luciferase mAb 1:2000 for 4°C overnight.  The cells were then washed twice in PBS and 
incubated in secondary antibody at 1:400 for 30 minutes.  The cells were washed twice and 
incubated for 5 minutes in 1:2000 DAPI.  Lastly, the cells were washed twice and suspended in 
500 µL of PBS.  Cells were fixed with either ProLong Anti-Fade mounting media (Molecular 
Probes, OR) or mounting media provided by Center for Biological Imaging (U. of Pittsburgh, 
PA).  Images were taken with Magnifire software. 
 
 
3.2 LUCIFERASE-BASED DRUG SCREEN 
3.2.1 Mice 
Swiss Webster female mice, 6 to 8 weeks old at the time of primary infection were used 
throughout the study.  The room temperatures were kept between 22 - 25°C and the mice were 
fed mouse pellets.  During transgenic parasite development, day 2 - 6 post-infection, the mice 
were given pyrimethamine supplemented drinking water.  The drinking water contains 7 mg/mL 
of pyrimethamine dissolved in DMSO and diluted 100 times with milliQ water.  For assay 
testing, the infected mice were give pyrimethamine supplemented drinking water on days 2 and 3 
post-infection.  All studies involving laboratory mice were performed in accordance with the 
IACUC guidelines on animal use and protocol. 
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3.2.2 Parasitological and Hematological Parameters 
Parasitic infections were monitored by thin smears of tail blood.  They were methanol-fixed and 
Giemsa-stained.  Parasitemia (P = % of infected erythrocytes) was determined by microscopy of 
the thin smears.  Luciferase activity and assay blood concentrations were kept at 5% hematocrit. 
 
3.2.3 Drugs 
Seven known antimalarial drugs were used to determine the sensitivity of the drug assay: 
pyrimethamine (MP Biomedicals, OH), primaquine (Sigma-Aldrich, MO), quinine (Sigma-
Aldrich, MO), atovaquone (Sigma-Aldrich, MO), tetracycline (Sigma-Aldrich, MO), artesunate 
(Sigma-Aldrich, MO), and amodiaquine (Sigma-Aldrich, MO).  Pyrimethamine was dissolved in 
DMSO to a final stock solution of 10 x 10³ µM and serial dilutions with complete culture 
medium were prepared, ranging from 1 - 100µM.  Primaquine was dissolved in water to a final 
concentration of 1 x 103 µM and serial dilutions with complete culture medium were prepared, 
ranging from 1 - 100µM.  Quinine was dissolved with 100% ethanol to a final concentration of 
100 µM and serial dilutions with complete culture medium were prepared, ranging from 0.1 – 
10µM.  Atovaquone was dissolved in DMSO to a final stock solution of 40 µM and serial 
dilutions with complete culture medium were prepared ranging from 5 x 10-4 - 5 x 10-2µM.  
Tetracycline and amodiaquine were dissolved in DMSO and ethanol respectively to a final 
concentration of 1 x104 µM.  They were serial diluted with complete culture medium ranging 
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from 10 – 1 x 103 µM.  Artesunate was dissolved with DMSO to a final solution of 20 µM and 
serial dilutions with complete culture medium were prepared, ranging from 0.01 - 1 µM.  
Unknown drugs L1, L3, and L4 were dissolved with DMSO to a final concentration of 200 µM 
and L2 to a final concentration of 100 µM.  All unknowns were serial diluted with complete 
culture medium ranging from 0.5 - 50 µM.  Complete media was 500 mL of RPMI 1640 with 
0.2% sodium bicarbonate, 2 mM L-glutamine, 10% (vol/vol) fetal bovine serum (FBS) and 2.5 
mg/mL gentamicin. 
Controls for the assay were as follows: complete culture media; 1% DMSO in complete 
culture media; 10% ethanol in complete culture medium; uninfected erythrocytes; and P. berghei 
infected erythrocytes. 
 
3.2.4 Optimization 
To establish the best conditions for the luciferase assay, the following parameters were 
optimized: parasitemia, hematocrit and temperature.  Once parasitemia reached 5%, the blood 
was harvested using 100 uL of 200 U/ml heparin solution through cardiac puncture.  The blood 
is transported at a temperature around 37°C and kept warm on a slide warmer.  Parasitemia at 5% 
was used with various hematocrits in a total of 100 µl medium and incubated in a 96-well plate.  
They were incubated at 37°C in 5% CO2, 5% O2 and 90% NO2.  After 24 hours, Steady-Glo 
Luciferase Assay System (Promega, WI) was performed according to the manufacturer’s 
instruction.  Briefly, 100 µl of the reagent was added in each well and incubated for five minutes 
to allow for lysis of erythrocytes, and then read with a luminometer (Veritas).  To validate the 
sensitivity of the assay, the 50% inhibitory concentration (IC50) values were calculated using 
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SigmaPlot software, version 12.0.  The IC50 values for each of the drugs from the transgenic 
parasites were compared to PbGFPLuxcon.  Each 96-well plate contained three wells of each 
control and antimalarial drug dilution at the highest concentration.  Images of infected blood 
with and without drug treatment were taken after 24 and 48 hours incubation under drug 
pressure.  The smears are stained with Giemsa stain and images are taken under a light 
microscopy using Magnifire software. 
3.2.5 Data Analysis 
IC50 values were calculated using pharmacology in SigmaPlot.  Standard curves analysis was 
done by using a four parameter logistics and a curve fit tolerance of 1 x 10-10.  The IC50 was 
calculated in three independent experiments from each construct.  The drugs IC50 values from 
PbGFPLuxcon were used as a control to compare their significance with Pb920Lux and 
Pb610Lux using GraphPad InStat software.  All comparisons had a sample size of three IC50 
values.  Gametocidal drugs IC50 values were calculated for significance using a one-sided t-test, 
while non-gametocidal drugs IC50 values were calculated for significance using a two-sided t-
test.  
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4.0  RESULTS 
4.1 SPECIFIC AIM 1 RESULTS 
4.1.1 Transgenic Parasite line that expresses luciferase 
Two new DNA vectors (Pb920Lux and Pb610Lux) were created to integrate the luciferase gene 
into the P. berghei genome.  Fig. 4 shows a general schematic representation of pL0027 and the 
general promoter regions for PBANKA_06920 and PBANKA_041610.  This vector contains 
previously described dhfr-ts gene of T gondii under the control of the dhfr-ts promoter of P. 
berghei.  Additionally, transfection of these plasmids would result in transgenic parasites that 
would express luciferase under the control of PBANKA_06920 and PBANKA_041610 
promoters.  PBANKA_06920 was chosen since this promoter permits the expression of 
luciferase in both male and female gametocytes, while PBANKA_041610 permits expression of 
luciferase only in male gametocytes [40].  Both promoters showed high levels of GFP expression 
during their previously stated phases [40] and therefore have proven to be great candidates for 
this luciferase vector.  The expression cassettes were cloned in competent cells and selected 
using their dhfr-ts drug selectable marker.  Both vectors were sequenced to confirm the ligation 
of the specific promoters into the luciferase expressing cassette. 
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They were linearized at a unique ApaI site within the dssurrna region of the vector (Fig. 
4C).  The linearized vectors (Pb920Lux and Pb610Lux) were introduced into purified schizonts 
by electroporation.   The dssurrna region of the plasmid is complementary to the c-rrna or d-
rrna unit found in the parasites genome.  Pyrimethamine resistant parasites were selected and 
partially cloned.  Partially cloned transgenic parasite contains untransfected PBANKA.  There 
was one partial clone for Pb920Lux and six partial clones for Pb610Lux.  Out of the six partial 
clones for Pb610Lux, two were selected to be characterized (Pb610.1Lux and Pb610.2Lux).  
 The correct insertion of the vectors into the c/ d-rrna unit was confirmed by PCR (Fig. 5).  
All three transgenic parasites were confirmed to be completely integrated into P. berghei (Fig. 
5A-C). 
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Figure 4. General Schematic of the Structure of PbLuxcon parasite? 
A schematic representation of PbLuxcon containing a general promoter site in the location of the 
desired promoter region for Pb920Lux and Pb610Lux.   
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Figure 5. Characterization of Transgenic Parasites? 
(A) Verification of the 5’ integration using primers L635 and L739.  (B) Verification of luciferase gene 
using LuxF and LuxR primers.  (C) Verification of 3’ integration using primers L665 and L740.  (D) 
Presence of wild-type PBANKA using primers L739 and L740.  Primer size and location (black arrows) 
are indicated on the vectors.  Each lane is as follows: Lane 1- 920Lux; Lane 2- 610.1Lux; Lane 3- 
610.2Lux 
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4.1.2 IFA of Transgenic Parasites 
To confirm that luciferase is only present during the gametocyte stage, we performed an 
Immunofluorescence assay (IFA) (Fig. 6).  In figure 6, PbGFPLuxcon is a transgenic parasite 
that constitutively expresses luciferase throughout the whole lifecycle.  It was used as a control 
to determine luciferase expression within the parasite.  All three shows the presence of the 
nucleus using DAPI (blue) and the presence of the parasites using PbHSP70 (green).  Since each 
parasite contains a single nucleus, the number of parasites within the cell can be enumerated.  
Next, we confirmed the presence of luciferase.  PbGFPLuxcon show the presence of luciferase in 
multinucleated RBCs that are infected with P. berghei, whereas both Pb920Lux and Pb610Lux 
show the presence of luciferase in a single nucleated RBC.  This suggests that Pb920Lux and 
Pb610Lux may express luciferase in gametocytes.  Bright Field images show the number of 
RBCs within the frame.  The limitation of this IFA is that we cannot completely confirm 
luciferase expression in gametocytes because we are not in possession of gametocyte specific 
antibody markers.  
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Figure 6. Luciferase Expression in Gametocytes. 
(A) PbGFPLuxcon is a transgenic parasite that constitutively expresses luciferase throughout whole 
lifecycle.  (B) Pb920Lux expresses luciferase during the sexual (gametocyte) stage.  (C) Pb610Lux 
expresses luciferase only in male gametocytes. All images were taken at 100X magnification. 
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4.2 SPECIFIC AIM 2 RESULTS 
4.2.1 Drug Dose Response and IC50 Comparison 
Drug response was monitored by measuring luciferase activity of the transgenic parasites after 
24 hours in the presence of three different concentrations of seven drugs.  We first set out to 
create an appropriate dose response for each transgenic parasite using the seven selected drugs 
(Fig. 7A-G).  Each transgenic parasite was injected into Swiss mice and allowed to reach a 
parasitemia of approximately 5%.  Once 5% parasitemia was reached, the blood was harvested, 
plated in a 96-well plate containing all seven drugs at their selected concentrations and incubated 
for 24 hours.  After 24 hours, luciferase activity measurements were taken and a dose response 
was calculated for each drug.   
 We compared the positive control (PbGFPLuxcon) to what has been previously reported 
(Table 2).  We found that PbGFPLuxcon produced similar IC50 drug values as previously 
reported values.  This confirms that our assay is sensitive enough to measure drug effects on 
mixed blood stages.  Next, we compared the IC50 drug values from PbGFPLuxcon and compared 
them to the IC50 values from Pb920Lux and Pb610Lux to PbGFPLuxcon (Table 3).  We 
hypothesized that any known drugs that have an effect on gametocytes will not have a 
significant different IC50 value from our transgenic parasites when compared to 
PbGFPLuxcon, while known drugs that do not have an effect on gametocytes will have a 
significant difference in IC50 values.  PbGFPLuxcon is a transgenic parasite that constitutively 
expresses luciferase, but does not contain a pyrimethamine resistant drug marker and is sensitive 
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to this drug. Whereas, our transgenic parasites do contain a pyrimethamine resistance gene and 
therefore we expect the difference in IC50 values to be significantly different for pyrimethamine.  
As expected, there was a significant difference of pyrimethamine IC50 values between 
PbGFPLuxcon to Pb920Lux and Pb610Lux (Fig. 8A).  Furthermore, we expected to find a 
significant difference of IC50 values of quinine, tetracycline and amodiaquine between our 
transgenic parasites and PbGFPLuxcon.  Although this was proven to be true for tetracycline 
(Fig. 8E), we found no significant difference of IC50 values for quinine and amodiaquine 
between PbGFPLuxcon and Pb610Lux (Fig. 8C and G).  As for antimalarial drugs (primaquine, 
atovaquone, and artesunate) that do have an effect on gametocytes, as expected there was no 
significant different in IC50 values (Fig. 8B, D and F). 
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Figure 7. Dose Response of Known Drugs? 
(A-G) Known antimalarial drug dose response of PbGFPLuxcon, Pb920Lux and.  Error bars are SEM.  
Each assay was done in triplicates and averaged to create the percentage of RLU. 
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Table 2. Summary of IC50 Values Calculated and Previously Reported 
 
 
Pyrimethamine* 0.006
Primaquine 15
Quinine 0.05
Atovaquone 0.003
Tetracycline 0.16
Artesusnate 0.018 +/- 0.002
Amodiaquine 0.012
0.17
0.014
0.011
Calculated IC50 
PbGFPLuxcon (µM)
0.425
14.735
0.03
0.004
In vitro resistance test/ Jelinek, 1995 (ref. #47)
Luciferase Assay/ Cui, 1995 (ref. #3)
In vitro resistance test/ Randrianairvelojosia, 2002                                                                                         
(ref. #46)
48hr Microtest/ Petersen, 1987 (ref. #45)
FACS/ Peaty, 2009 (ref. #3)
FACS/ Peaty, 2009 (ref. #3)
FACS/ Peaty, 2009 (ref. #3)
Drug Reported IC50  (µM) Assay type/ Source (ref. #)
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Table 3. Summary of IC50 Values 
 
Pyrimethamine* 0.425 15.06
Primaquine 14.735 11.061
Quinine 0.03 5.47
Atovaquone 0.004 0.012
Tetracycline 0.166 138
Artesunate 0.014 0.378
Amodiaquine 0.011 9.3
Drug Expected Results
Calclulated IC50 
PbGFPLuxcon (µM)
0.002
172.36
Calculated IC50 
PB610Lux (µM)
5.67
Calculated IC50 
PB920Lux (µM)
0.087
15.938
1.5
11.796
 39 
Pyrimethamine*
IC
50
 (u
M
)
0
1
5
10
15
20
Pb
GF
PL
ux
co
n
Pb
92
0L
ux
Pb
61
0L
ux
P=0.0463
P=0.0071
Primaquine
IC
50
 (u
M
)
0
5
10
15
20
25
Pb
GF
PL
ux
co
n
Pb
92
0L
ux
Pb
61
0L
ux
Quinine
IC
50
 (u
M
)
0.00
0.05
2
4
6
8
10
Pb
GF
PL
ux
co
n
Pb
92
0L
ux
Pb
61
0L
ux
P=0.0107
Atovaquone
IC
50
 (u
M
)
0.000
0.005
0.010
0.015
0.020
0.025
Pb
GF
PL
ux
co
n
Pb
92
0L
ux
Pb
61
0L
ux
Tetracycline
IC
50
 (u
M
)
0.0
0.3
150
200
250
Pb
GF
PL
ux
co
n
Pb
92
0L
ux
Pb
61
0L
ux
P=0.0104
P=0.0336
Artesunate
IC
50
 (u
M
)
0.00
0.05
0.10
0.15
0.4
0.5
0.6
Pb
GF
PL
ux
co
n
Pb
92
0L
ux
Pb
61
0L
ux
Amodiaquine
IC
50
 (u
M
)
0.00
0.02
5
10
15
20
Pb
GF
PL
ux
co
n
Pb
92
0L
ux
Pb
61
0L
ux
P=0.0385
A. B.
C. D.
E. F.
G.
 
Figure 8. IC50 Comparisons of Transgenic Parasites? 
(A-G) IC50 values of known antimalarial drugs from PbGFPLuxcon, Pb920Lux and Pb610Lux 
in.  Error bars are SEM.  Each IC50 was averaged.  Pb920Lux and Pb610Lux IC50 values 
compared to PbGFPLuxcon using a t-test. 
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4.2.2 Microscopic Examination of Known Drug Compounds 
In order to further validate the accuracy of this luciferase assay, we calculated the percentage of 
parasites and gametocytes from infected blood under no drug treatment, tetracycline treatment 
and atovaquone treatment after 24 hours (Fig. 9).  Tetracycline and atovaquone smears were 
taken at the highest serial concentration of 1x103 µM and 0.05 µM, respectively.  After 24 hours, 
infected blood had approximately 4% parasitemia with approximately 9% of the mixed parasite 
population being gametocytes.  Tetracycline treated infected blood had approximately 3% 
parasitemia with 9% of those being gametocytes.  Atovaquone had 4% parasitemia with 
approximately 4% of those being gametocytes. 
 Blood smears were taken at 24 hours and 48 hours (Fig. 10).  Infected blood 
(gametocytes) with no drug treatment at 24 hours looks approximately the same as non-treated 
infected blood at 48 hours, while infected blood treated with 1x103 µM of tetracycline at 24 and 
48 hours shows slightly abnormal gametocytes.  The gametocytes have caused the usual 
enlargement of erythrocytes, but the purplish color of the gametocytes and their nuclei are 
slightly off color.  In addition, there seems to be an abundance of brown granules accumulating 
within the parasite at both time frames.  Infected blood treated with 0.5 µM of atovaquone at 24 
and 48 hours shows abnormal gametocytes.  At both time frames, the gametocytes has caused the 
usual enlargement of erythrocytes, but the parasite no longer has the purplish stain shown in the 
untreated gametocytes.  Furthermore, they show the same accumulation of brown granules that 
were shown the tetracycline treated gametocytes.  The nuclei in the atovaquone treated 
gametocytes were still well defined.  
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Figure 9. Percentage of Parasites and Gametocytes? 
(A and B)  Blood smears were taken after 24 hours.  (A) The percentage of parasites and (B) gametocytes 
is their amount over the number of RBC. Both parasitemia and gametocytaemia was microscopically 
counted.  This experiment was done in triplicate and error bars are SEM. 
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Figure 10. Microscopic Images after 24 hours and 48 hours. 
(Left) Microscopic images of infected RBCs after 24 and 48 hours.  (Middle) Microscopic images of 
infected RBCs treated with 1x103 µM of tetracycline after 24 and 48 hours.  (Right) Microscopic images 
of infected RBCs treated with 0.05 µM of atovaquone for 24 and 48 hours. All images were taken at 100x 
magnification. 
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4.2.3 Effects of Unknown Drugs Compounds 
Once the luciferase assay was validated, we then wanted to do a sample assay on a couple of 
unknown drugs to see their affect against gametocytes (Fig. 11).  The effect of L1 on 
PbGFPLuxcon, Pb920Lux and Pb610Lux doesn’t show a dose response (Fig. 11A).  L1 showed 
a 40 - 50% decrease in PbGFPLuxcon and Pb920Lux, while Pb610Lux had no effect.  L2 did 
show a dose response with PbGFPLuxcon, but no dose response was seen for Pb920Lux and 
Pb610Lux (Fig. 11B).  This drug did cause a 40 - 60% decrease of Pb920Lux, but had no effect 
on Pb610Lux.  L3 showed a minor dose response for PbGFPLuxcon, but there was no dose 
response for Pb920Lux or Pb610Lux (Fig. 11C).  This drug also had no effect on Pb610Lux.  L4 
on had no effect on any of the transgenic parasites.  Interestingly, at 5µM the inhibitory effect of 
the drug seems to weaken before returning to approximately 40 - 50% inhibition.  Furthermore, 
this drug along with the others had no effect of Pb610Lux.   
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Figure 11. Dose Response of Unknown Drugs. 
(A-D) PbGFPLuxcon, Pb920Lux and dose response of unknown drugs (L1-L4).  Each assay was done in 
once. 
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5.0  DISCUSSION 
To our knowledge, luciferase based drug assays are the simple and most efficient way to study 
the effect of drug compounds on Plasmodium, but as drug assay techniques have advanced over 
the last couple of years the way to analyze the drug effects on gametocytes has not advanced as 
quickly.  The best way to study a drug’s effect on gametocytes would be to use the human strain 
P. falciparum; this would come with its own challenges.  As previously stated, P. falciparum 
gametocytes take longer to develop as compared to P. berghei and over time in vitro cultured P. 
falciparum can lose their ability to produce gametocytes [39].  In addition, cultivation systems 
may be effective at producing viable P. falciparum gametocytes, but at a cost of expensive 
equipment and high rates of contamination.  Therefore, the best alternative has been working 
with P. berghei to screen for possible antimalarial drugs.  P. berghei allows for the study of 
antimalarial drugs in vitro as well as in vivo and tends to have the same drug susceptibility as P. 
falciparum.   
Transgenic P. berghei parasites expressing GFP-Luciferase have been generated before 
[37].  However, the disadvantage of these transgenic parasites is the inability to quickly and 
efficiently study the effect of drug candidates on the gametocyte stage of the parasite since both 
asexual and sexual stages express luciferase.  In our study we were able to identify and create 
two transgenic parasites that sufficiently express luciferase, one in gender mixed gametocytes 
and the other in the male gametocyte.  One advantage is that unlike previous studies using 
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PbGFPLuxcon [42], we were able to reduce the amount of labor required to do an assay by 
eliminating the process of separating gametocytes from the asexual blood stage.  This allowed us 
to use these transgenic parasites for a simple and efficient luciferase-based drug assay.  Another 
advantage of our transgenic parasites is that not only can we study the overall effects of drugs on 
gametocytes, but we can also distinguish their effect on the male gametocyte.   
Creating transgenic parasites that expresses luciferase in gametocytes has allowed us to 
develop and standardize a luciferase-based drug assay using seven known antimalarial drugs.  
Four of the seven drugs had a known effect on gametocytes, while the other three had no known 
effect.  In order to confirm the optimization of our assay, we tested the antimalarial drugs IC50 
values from PbGFPLuxcon to those previously reported.  We found that our calculated drug IC50 
values were similar to those previously reported and therefore confirmed the optimization of our 
assay (Table 2).  Next, we tested the effects of the seven known antimalarial drugs using our 
transgenic parasites.  We hypothesized that using our transgenic parasites; gametocidal drugs 
would show a similar IC50 when used with PbGFPLuxcon (control), while those with no known 
gametocidal activity would show a significantly higher IC50 (Table 3).  We found that 
pyrimethamine and tetracycline IC50 values were both significant for Pb920Lux and Pb610Lux, 
while quinine and amodiaquine IC50 values were only significant for Pb920Lux (Table 4).  This 
may be explained by many different factors which include the possibility that Pb610Lux may be 
more sensitive to these drugs.  This cannot be confirmed without creating a transgenic parasite 
that expresses luciferase in the female gametocyte.  As expected for the antimalarial drugs that 
have gametocidal activity (primaquine, atovaquone, and artesunate), there was no significant 
difference in their IC50 values (Table 4).  Table 4 is the comparative summary of Pb920Lux and 
Pb610Lux to PbGFPLuxcon. 
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Table 4. Comparative Summary of Transgenic Parasites 
 
 
 
  
Pyrimethamine* 0.0072 Y
Primaquine 0.853 N
Quinine 0.0107 Y/N
Atovaquone 0.395 N
Tetracycline 0.0336 Y
Artesunate 0.0836 N
Amodiaquine 0.0385 Y/N
Drug SignificanceExpected Results
 PbGFPLuxcon/ 
Pb920Lux           
(P-value)
0.0852
PbGFPLuxcon/ 
Pb610Lux           
(P-value) 
0.0463
0.1057
0.143
0.4964
0.0104
0.0721
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Next, we wanted to test the sensitivity of our luciferase-based drug assay 
microscopically.  Microscopic analysis of the effect of a drug on Plasmodium has been the gold 
standard and therefore we wanted to confirm our results with what we can see microscopically.  
Our results gave us approximately 4% parasitemia for non-treated infected blood, which was 
similar to that of tetracycline and atovaquone.  While the percentage of gametocytes in the 
infected blood and tetracycline were similar, there was a marked difference with atovaquone. In 
addition, we noticed that the gametocytes in the non-treated infected blood looked significantly 
different from those treated with tetracycline and atovaquone.  Both drugs show transgenic 
parasites had an accumulation of brown granules; in addition atovaquone treated gametocytes 
completely lost their purplish stain.  Therefore, we extended the drug treatment for 48 hours to 
see if there was significant affect.  Although we did not see any difference in the blood smears 
that were taken at 24 and 48 hours, we did see the same differences of the drug treated 
gametocytes from the untreated.  This may be explained by the fact that tetracycline causes 
abnormal cell division [30] and although tetracycline doesn’t have a significant effect on 
gametocytes it is still causing an effect that may be a stress response.  Whereas, atovaquone does 
have an effect on gametocytes electron transport and therefore the parasite may look relatively 
normal, it is no longer functioning properly.  Thus, the gold standard may be counting parasites 
by light microscopy; a potential problem with this is the inability of distinguishing dead or dying 
parasites from healthy one as well as distinguishing immature gametocytes from mature ones.   
After we validated our luciferase-based assay, we then wanted to test it on a set of 
unknown drugs.  These drugs were used in a previous study to analyze their effects on different 
Plasmodium spp. [44].  Although the identities of the drug compounds are unknown, we do 
know that they are fatty acids derivatives that are extremely unstable and were in limited supply 
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within our laboratory.  There have been a few reports that have shown fatty acids displaying 
antimalarial activity [44-47].  These particular unknown are isometric C16 acetylenic fatty acids, 
whose mechanism of action is suspected to be related to the position of the triple bond in a C16 
acyl chain [44].  We wanted to see if there was any gametocidal activity among these four 
unknown drugs and therefore we set up serial dilutions to get a dose response.  Due to their 
instability, we were only able to set on a single assay for all three parasites.  Our conclusion is 
that none of these drugs show any gametocidal activity, although to truly confirm, these 
experiments would have to be done at least two more times.    
The renewed interest in stopping the transmission of malaria is not only a noble goal, it is 
probable, but until a vaccine is created, the next best thing is to find additional antimalarial 
drugs.  In order to do that, we needed to develop simple and efficient methods for screening large 
library of drug compounds.  In this study we used firefly luciferase; the advantage of our 
luciferase-based assay is the low background noise, which allows for easy analysis of the 
samples.  The protocol was designed to involve the least amount a steps while giving optimal 
results.  By creating a transgenic parasite line that expresses luciferase in gametocytes, we have 
reduced the amount of labor it takes to purify gametocytes for antimalarial testing.  Additionally, 
by creating a luciferase-based assay there was no need to filter out any background noise because 
unlike fluorescence, photons are not required to be in an excited state and therefore does not 
produce an inherent background when measurements are taken. 
A limitation of working with P. berghei parasites is the inability to synchronize the 
infection; although we did not detect many discrepancies when comparing the known 
antimalarial drugs’ IC50 values from our transgenic parasites to PbGFPLuxcon, this may explain 
the various degrees of significance (Table 4).  Another limitation of our luciferase-based assay is 
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that were not able to test its sensitivity with a transgenic parasite that expresses luciferase in 
female gametocytes.  This would have allowed us to compare our results with the luciferase 
expressed in male gametocyte to those in female gametocytes.  This would allow us to confirm 
or deny the sensitivity of male gametocytes to the known drugs.  The importance is one gender 
may be more sensitive to a drug and therefore, even if you don’t see a significant difference in 
gametocytes drug sensitivity overall, transmission can still effectively be inhibited.  Although, a 
previous study affirms that the promoters we attached to the luciferase reporter is expressed in 
mixed gametocytes and male gametocytes [40], we would have to confirm those findings with a 
mixed gametocyte and a male gametocyte antibody marker.  An additional limitation of our 
assay is most antimalarial drugs must be metabolized in the liver to allow for maximal effect, 
while our in vitro model only results in limited drug effects.  Even with those disadvantages we 
believe, our luciferase-based drug assays is one of the best and easy methods to screen for 
antimalarial drugs.  Luciferase-based assays are not only quick and easy, they also produce 
virtually no background noise, this allows for a sample to be using in a high-throughput 
screening, which is normally done in a 384-well plate. 
We have shown that these transgenic parasites that express luciferase in gametocytes can 
be using in a gametocyte-specific drug-screening assay. Although, we only tested this with a 
small sample of drug compounds, future studies would include decreasing the sample volume to 
allow for use in a 384-well plates and testing substantially more drug compounds. These 
transgenic parasites can also be used for screening drugs with gametocidal activity in in vivo 
infections in rodents. In addition, creating a transgenic parasite that expresses luciferase in 
female gametocytes would allow for better comparison of different drugs effects on sex-specific 
gametocytes.  Furthermore, future studies would include fusing GFP to luciferase, to aid in the 
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analysis of gametocytes.  The significance of this luciferase-based assay is that this is a quick 
and easy method to detect compounds that have an antimalarial effect not only in gametocytes, 
but more specifically in male gametocytes.  In this study we used unknown fatty acid compounds 
and although we were unable to detect any gametocidal activity, this assay can be used to screen 
various unknown compounds.  Lastly, this assay seems to detect gametocytes in the early as well 
as the late stages and therefore can detect the effects of gametocidal drugs in earlier stages, 
which is something that has not been done before using a luciferase assay.  By providing a 
simple and sensitive method for screening gametocidal drugs, this can add to the broad efforts of 
the eradication of malarial worldwide.  
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